Table 1.
Histopathological characterization of PXA patients
| PXA patients | Diagnosis | Gender, age | ICH features | Brain localization |
|---|---|---|---|---|
| |
|
|
BRAF V600E negative (no mutation) |
|
| CD34 positive. | ||||
| PXA-1 |
PXA WHO grade II |
18y., female |
GFAP positive. |
right frontal |
| |
|
|
MIB-1:1% |
|
| |
IDH1 R132H negative (no mutation). |
|
||
| |
|
|
GFAP positive. |
|
| PXA-2 |
PXA WHO grade II |
17y., female |
MIB-1: 1%. |
right temporal |
| |
|
|
No tumor tissue available for BRAF/CD34 characterization |
|
| |
|
|
BRAF V600E positive (mutated) |
|
| CD34 focal positive | ||||
| PXA-3 |
PXA WHO grade II |
34y., female |
GFAP. Positive. |
left temporal |
| |
|
|
MIB-1: <1%. |
|
| |
IDH1 R132H negative (no mutation) |
|
||
| |
|
|
BRAF V600E negative (no mutation) |
|
| CD34 positive | ||||
| Mitotic index <5 mitoses/10 HPF | ||||
| PXA-4 precursor of PXA-5 |
PXA WHO grade II |
59y., male |
Immunopositivity for GFAP, S100, MAP2, |
right parietal |
| |
|
|
vimentin and EMA |
|
| |
MIB-1: 5-10% |
|
||
| |
IDH1 R132H negative (no mutation) |
|
||
| |
|
|
BRAF V600E negative (no mutation) |
|
| CD34 positive | ||||
| Mitotic index >5mitoses/10 HPF | ||||
| PXA-5 |
PXA with anaplastic features |
59y., male |
Immunopositivity for GFAP, S100, MAP2, |
right parietal |
| |
|
|
vimentin and EMA |
|
| |
MIB-1: 10-15% |
|
||
| |
IDH1 R132H negative (no mutation) |
|
||
| |
|
|
BRAF V600 E negative (no mutation) |
|
| CD34 positive | ||||
| PXA-6 |
PXA with anaplastic features |
22y., male |
GFAP positive |
right temporal |
| |
|
|
MIB-1: 5%. |
|
| |
IDH1 R132H negative (no mutation) |
|
||
| |
|
|
BRAF V600 E negative (no mutation) |
|
| CD34 positive | ||||
| PXA-7 |
PXA WHO grade II |
44y., female |
Immunopositivity for GFAP |
right temporal |
| |
|
|
MIB-1: 1%. |
|
| |
IDH1 R132H negative (no mutation) |
|
||
| |
|
|
BRAF V600 E negative (no mutation) |
|
| CD34 positive | ||||
| PXA-8 |
PXA WHO grade II |
20y., male |
Immunopositivity for GFAP. |
right parieto-occipital |
| |
|
|
MIB-1: <1%. |
|
| |
IDH1 R132H negative (no mutation) |
|
||
| |
|
|
BRAF V600 E negative (no mutation) |
|
| CD34 positive | ||||
| PXA-9 |
PXA WHO grade II |
78y., female |
Immunopositivity for GFAP. |
right temporo-parietal |
| |
|
|
MIB-1: <1%. |
|
| |
IDH1 R132H negative (no mutation) |
|
||
| PXA-10 |
PXA WHO grade II |
15y., female |
BRAFV600E negative (no mutation) |
right occipital |
| CD34 positive | ||||
| Immunopositivity for GFAP. | ||||
| |
MIB-1: 1%. |
|
||
| PXA-11 |
PXA WHO grade II |
52y., male |
BRAFV600E negative (no mutation) |
left occipital |
| CD34 positive | ||||
| Immunopositivity for GFAP. | ||||
| |
MIB-1: < 1%. |
|
||
| PXA-12 |
PXA WHO grade II |
17 y., male |
BRAFV600E positive (mutated) |
left parietal |
| CD34 negative | ||||
| Immunopositivity for GFAP. | ||||
| |
MIB-1: 1%. |
|
||
| PXA-13 | PXA WHO grade II | 37 y., female | BRAFV600E positive (mutated) |
right parietal |
| CD34 focal positive | ||||
| Immunopositivity for GFAP | ||||
| MIB-1: < 1% | ||||
Patients undergoing surgical resection of diagnosed pleomorphic xanthoastrocytoma of diverse grade were investigated for specific features characteristic of this tumor type.